Peptides for focus, mood and the brain, ranked by human evidence

Peptides studied for attention, memory, mood, stress and brain injury. Human evidence is thin for most; the ranking makes clear which few carry real trials. They are ranked by an evidence score that weighs the grade of the evidence, the human trials counted in PubMed, and regulatory status — shown in the columns so any rank can be checked. A high score means a peptide is well studied and often approved for something, not that it is right, safe or legal for this goal. Nothing here is medical advice, and Grey Peptides sells nothing and links to no vendor. See all goals or the plainer browse by goal map.

Evidence grade

Regulatory status

Search name

Has a human trial on this page

55 peptides · sorted by evidence score (click a column to re-sort)

Peptide	Grade	Human studies	RCTs	Max trial phase	Regulatory	Dose	Score
Trofinetide	High	54	9	Phase 3	FDA approved	oral →	100
Cerebrolysin	High	348	62	Phase 4	Approved abroad	—	90
Ziconotide	High	276	4	Phase 4	FDA approved	—	90
Nerinetide	Medium	1,354	45	Phase 3	In trials	—	70
Sovateltide	Medium	52	2	Phase 4	Approved abroad	—	70
Pegsebrenatide	Medium	12	1	—	In trials	injection →	70
Amilomotide	Medium	10	2	—	Approved abroad	intramuscular →	70
Rovatirelin	Medium	4	1	—	In trials	—	70
Neurotensin	Medium	2,211	48	Phase 4	Research only	—	65
Galanin	Medium	1,341	25	—	Research only	—	65
PACAP	Medium	1,341	36	Phase 4	Research only	—	65
Nemifitide	Medium	18	6	—	Discontinued	subcutaneous →	65
Posatirelin	Medium	8	2	—	Discontinued	intramuscular →	65
Davunetide	Medium	119	10	Phase 3	In trials	intranasal →	60
Semax	Medium	54	1	—	Approved abroad	—	60
Selank	Medium	45	3	—	Approved abroad	—	60
Taltirelin	Medium	22	0	Phase 4	Approved abroad	oral →	60
Beta-Endorphin	Medium	7,648	477	Phase 4	Research only	—	55
Neuropeptide Y	Medium	6,034	149	Phase 4	Research only	—	55
Enkephalin	Medium	4,742	89	Phase 3	Research only	—	55
DSIP	Medium	141	6	—	Research only	—	55
Noopept	Medium	31	0	—	Approved abroad	—	50
Dynorphin	Low	9,350	190	Phase 4	Research only	—	45
Nociceptin	Low	694	15	Phase 4	Research only	intravesical →	45
Endomorphin-1	Low	210	9	—	Research only	—	45
Neuropeptide S	Low	193	1	Phase 4	Research only	—	45
Colostrinin	Low	30	2	—	Supplement	oral (sublingual) →	45
Ebiratide	Low	4	1	—	Discontinued	intravenous (research) →	45
Cortexin	Low	3,669	46	—	Approved abroad	intramuscular or intravenous →	40
P21	Low	25,382	52	Phase 2	Research only	—	35
Orexin-A	Low	2,184	47	Phase 4	Research only	—	35
Orexin-B	Low	2,005	44	Phase 4	Research only	—	35
Montirelin	Low	268	20	Phase 4	Discontinued	—	35
Kyotorphin	Low	133	3	Phase 4	Research only	—	35
Deltorphin	Low	74	1	—	Research only	—	35
PE-22-28	Low	18	1	—	Research only	—	35
Manserin	Low	3	0	—	Research only	—	35
Leconotide	Low	1	0	—	Approved abroad	—	30
Apamin	Low	480	0	—	Research only	—	25
Prokineticin 2	Low	234	0	—	Research only	—	25
Neuropeptide FF (NPFF)	Low	169	0	—	Research only	—	25
Relaxin-3	Low	152	0	—	Research only	—	25
Neuromedin N (NN)	Low	47	0	—	Research only	—	25
Nocistatin (NST)	Low	27	0	—	Research only	—	25
Glypromate	Low	24	0	—	Research only	—	25
Neuromedin S	Low	18	0	—	Research only	—	25
Adamax	Low	14	0	—	Research only	—	25
Dihexa	Low	9	0	—	Research only	—	25
TCAP-1 (Teneurin C-terminal Associated Peptide-1)	Low	9	0	—	Research only	—	25
Neuropeptide EI (NEI)	Low	7	0	—	Research only	—	25
Azetirelin	Low	3	0	—	Discontinued	—	25
FGL Peptide	Low	1	0	—	Research only	—	25
BRN2 (POU3F2) Research Peptide	Low	0	0	—	Research only	—	20
NA-Selank Amidate	Low	0	0	—	Research only	—	20
NPAS3 Research Peptide	Low	0	0	—	Research only	—	20

Other goals: Weight loss and metabolism · Healing, injury and recovery · Skin and hair · Growth hormone and body composition · Heart and circulation · Sexual and reproductive health · Longevity and cell health · Immune defence and infection · Diagnostic and research tools · In development

How the evidence score works

Evidence score (0-100), a transparent ranking aid, not a verdict. grade: high=60, medium=40, low=20, ungraded=0. Human trial: an on-site read-and-cited randomized or clinical trial = +15, else any PubMed human-indexed record = +5, else 0. RCT literature: PubMed lists >=1 randomized controlled trial = +10. Regulatory: FDA-approved = +15, in trials / approved-abroad / in development = +5, else 0. Every component is stored on each record so the number can be re-derived; volume and grade are shown together so neither misleads.

“Human studies” and “RCTs” are PubMed record counts for the peptide (read 2026-11-07 from the counts behind the Evidence Explorer); a count is how much research exists and of what kind, never proof a peptide works. “Grade” is our editorial reading of the evidence — see how we grade evidence. The “Dose” column links to the entry for each peptide that carries a dose from a regulator’s label or a published human study — where the amount is shown with its source; the amount is never reprinted here without that source, and many research peptides have no human dose, shown as —. Of 660 peptides, 607 have at least one human-indexed PubMed record, 324 cite a human trial on their page, 124 are FDA-approved, and 271 carry a sourced dose.